. Rigal-l, S. Sidorkiewicz, J. M. Treluyer, E. Perrodeau, C. Le et al., Titrated baclofen for high-risk alcohol consumption: A randomized placebocontrolled trial in outpatients with one-year follow up, Addiction, 2019.

C. Palpacuer, . Duprez-r, . Huneau-a, . Boussageon-r, C. Locher et al., Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen, and topiramate, Addiction, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01696955

. Naudet-f, . Braillon-a.-baclofen, and . France, Lancet Psychiatry, vol.5, pp.961-962, 2018.

. Doshi-p, K. Dickersin, . Healy-d, . S. Vedula-s, and . Jefferson-t, Restoring invisible and abandoned trials: a call for people to publish the findings, Bmj, p.346, 2013.

. Freedman-b, Equipoise and the ethics of clinical research, N Engl J Med, vol.317, pp.141-145, 1987.

, International guide for monitoring alcohol consumption and related harm, 2000.

. Jaury-p, Traitement de l'alcoolisme -Essai thérapeutique pragmatique randomisé, en double insu pendant un an en milieu ambulatoire du baclofène versus placebo. SFA, 2017.

C. Chaignot, M. Zureik, . Rey-g, . Dray-spira-r, J. Coste et al., Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between, Pharmacoepidemiology and drug safety, vol.27, pp.1239-1248, 2009.

P. Ducimetiere, C. Cornu, B. Guinhouya, . Laslop-a, and . Mantua-v, , 2018.

J. P. Ioannidis, . J. Evans-s, . C. Gotzsche-p, . T. O'neill-r, . G. Altman-d et al., Better reporting of harms in randomized trials: an extension of the CONSORT statement, Annals of internal medicine, vol.141, pp.781-788, 2004.